$NUVL

Srivastava Sapna sold (to issuer) 3,444 shares of NUVL

Srivastava Sapna sold (to issuer) 3,444 shares of Nuvalent, Inc. (NUVL) on 2026-07-15.

Original reporting
SEC EDGAR · Srivastava Sapna
Published Jul 15, 2026, 11:07 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 15, 2026, 11:10 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$NUVL
Neutral
high confidence
Mentioned
$NUVL
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NUVLNeutralLow
01

Why it matters

The newest fact is the director’s sale of 3,444 shares to the issuer on 2026-07-15, leaving 0 shares reported after the transaction.

02

Market read

Traders may note insider selling, but the filing lacks price and broader corporate context, limiting actionable signal strength.

03

What to watch

The article does not state whether the sale is part of any compensation or liquidity program beyond noting no pre-arranged 10b5-1 plan, nor does it provide context on prior holdings or future grants.

Relevance 3/10Novelty 3/10Timing: Filed 2026-07-15, after-hours SEC Form 4 disclosure

Background

The article is an SEC Form 4 insider transaction disclosure for Nuvalent, Inc. (NUVL).

Company-level read

Ticker impact

$NUVLNeutralHigh confidence
Context

Nuvalent director Sapna Srivastava sold 3,444 shares to the issuer on 2026-07-15, with post-transaction holdings at 0 shares.

Expected impact

Likely minimal near-term impact; any effect would be sentiment-only and small.

Evidence & confidence

The filing is a Form 4 insider transaction, but the article provides no price, no buyback size, and no accompanying corporate or operational catalyst.

Market effects

No sector read-through; this is company-specific insider transaction data only.

None indicated.

None indicated.

Counterpoint

A sale to the issuer can be administrative (for example, plan mechanics) and may not reflect bearish expectations; the lack of disclosed price reduces interpretability.

Key entities

  • Nuvalent, Inc.

    Company whose director insider sale to the issuer is disclosed on SEC Form 4.

  • Srivastava Sapna

    Director who sold 3,444 shares to the issuer on 2026-07-15.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$GSKMedAI 8/10

GSK completes acquisition of Nuvalent, Inc

GSK said it has completed its acquisition of Nuvalent (NASDAQ: NUVL) via a tender offer. The deal adds three lung cancer assets, including zidesamtinib (NVL-520) and neladalkib (NVL-655) under FDA review, plus NVL-330 in phase I. Transaction value is about $10.6B (£8.0B), net investment about $9.4B (£7.1B).

$MRVLMed

Stocks Erase Early Gains as Chipmakers Turn Lower

US stocks pared early gains as chipmakers and software firms fell. Marvell, Qualcomm, ARM and others dropped, while ServiceNow and Salesforce also declined. Treasury yields were pressured by a $58B 3-year auction and stronger May existing home sales. In Europe, Bund and gilt yields fell; swaps price a 100% chance of a 25 bp ECB hike. UNFI slid after Q3 sales missed; Nuvalent surged on a $10.6B GSK buyout.

$MUMed

More swings for AI stocks drag Wall Street back on the roller coaster

Wall Street swung as AI-related chip and memory stocks reversed after early gains. The S&P 500 fell 0.3% (7,386.65), the Nasdaq dropped 1% (25,678.82), and the Dow rose 0.2% (50,872.11). Micron slid 1.4% after a 10% drop; it had surged 9.9% Monday. Oil eased (Brent -3% to $91.45) but AI weakness outweighed. GSK agreed to buy Nuvalent for $10.6B, sending Nuvalent up 39.3%.

$COHRMed

Benzinga

U.S. stocks fell Tuesday as rotation out of chip and AI leaders resumed: Nasdaq 100 -3.3% to ~28,437, S&P 500 -1.6% to ~7,228, Dow -0.5% to ~50,535. Oil dropped ~6% and markets priced ~50% odds of a Fed hike by October ahead of Wednesday’s CPI. Tech led declines (XLK -5.1%); SMH fell as COHR -15.2%, MRVL -12.1%, LITE -11.8%.

$GSKHighAI 9/10

GSK Strikes $10.6B Nuvalent Deal Strengthening Targeting Cancer Pipeline

GSK agreed to acquire Nuvalent for $10.6B (£8.0B) to strengthen its late-stage oncology pipeline. GSK will tender for all Nuvalent shares at $124 cash, a 40% premium; net investment is $9.4B. Nuvalent’s FDA-review candidates Zidesamtinib and Neladalkib have 2026 decision dates. Deal expected to close in Q3 2026; GSK said 2026 outlook and 70p dividend remain unchanged.

$GSKHighAI 9/10

GSK Makes Its Biggest Bet In More Than A Decade, Paying $10. 6 Billion For Cancer Drug Developer Nuvalent

GSK will acquire Nuvalent for $10.6 billion, buying all outstanding shares for $124 cash each, a 40% premium to Nuvalent’s last close of $88.49. Nuvalent shares rose about 39% in premarket. GSK expects revenue growth and accretion to sales and core operating profit from 2027, and higher core EPS from 2029, gaining lung cancer assets including zidesamtinib and neladalkib.